BioSpace News Archive

IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today highlighted recent business updates and provided pipeline goals for 2024.

Pfizer Canada ULC announces today the Health Canada approval of ABRYSVOTM, its bivalent Respiratory Syncytial Virus (RSV) vaccine.

AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2023 financial results on Friday, February 2, 2024, before the market opens.

FibroBiologics, Inc. announced that it will attend the Biotech Showcase in San Francisco, CA from January 8-10, 2024.

Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases, announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global.

Artax Biopharma, Inc. announces important changes and expansions to its Executive Team as the Company enters its critical next phase.

Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, highlighted recent progress across the company’s cell and gene therapy portfolio and provided updates on anticipated upcoming milestones.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 10 new employees.

Immunexpress, Pty Ltd. announced today the clearance of EDTA blood compatible cartridges by the U.S. Food and Drug Administration (FDA) for use with SeptiCyte RAPID®.

OnQuality Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for our OQL025 Investigational New Drug (IND) application, with an indication to treat Epidermal Growth Factor receptor (EGFR) inhibitor-induced acneiform rash, a common toxicity affecting patients treated with EGFR inhibitor therapy.